Projets financés Early detection and prevention of cardiac dysfunction and heart failure induced by cancer chemotherapeutics – Cardio-oncology ERA-CVD 2016 Plus de détails de : Early detection and prevention of cardiac dysfunction and heart failure induced by cancer chemotherapeutics Communication between cardiomyocytes and innate immune cells in failing hearts – CLARIFY ERA-CVD 2016 Plus de détails de : Communication between cardiomyocytes and innate immune cells in failing hearts DETERMINING THE ROLE OF CLINICAL AND EPI-GENETIC RISK MARKERS IN DILATED CARDIOMYOPATHIES AND HEART FAILURE – DETECTIN-HF ERA-CVD 2016 Plus de détails de : DETERMINING THE ROLE OF CLINICAL AND EPI-GENETIC RISK MARKERS IN DILATED CARDIOMYOPATHIES AND HEART FAILURE Heart Failure Rescue by Nutritional Approaches: relevance of mitochondrial substrate utilization – FAT4HEART ERA-CVD 2016 Plus de détails de : Heart Failure Rescue by Nutritional Approaches: relevance of mitochondrial substrate utilization Metabolic Therapy for Managing Diastolic Heart Failure – MINOTAUR ERA-CVD 2016 Plus de détails de : Metabolic Therapy for Managing Diastolic Heart Failure Gene therapy with phosphodiesterases to treat heart failure – PDE4HEART ERA-CVD 2016 Plus de détails de : Gene therapy with phosphodiesterases to treat heart failure Novel RNA based therapies for treatment-resistant forms of severe cardiomyopathy caused by LMNA mutations – VARIATION ERA-CVD 2016 Plus de détails de : Novel RNA based therapies for treatment-resistant forms of severe cardiomyopathy caused by LMNA mutations Targeted LYmphatic and MIcrovessel Treatments in metabolic-DISease HFpEF – LYMIT-DIS ERA-CVD 2016 Plus de détails de : Targeted LYmphatic and MIcrovessel Treatments in metabolic-DISease HFpEF LIPCAR, a prognostic marker of heart failure with reduced ejection fraction – LIPCAR-HF ERA-CVD 2016 Plus de détails de : LIPCAR, a prognostic marker of heart failure with reduced ejection fraction Exploring new pathways in age-related heart diseases – EXPERT ERA-CVD 2016 Plus de détails de : Exploring new pathways in age-related heart diseases Cardiomyocyte - non myocyte interplay as a novel platform for mechanistic insights and therapeutic approaches in ACM heart failure – ACM-HF ERA-CVD 2016 Plus de détails de : Cardiomyocyte - non myocyte interplay as a novel platform for mechanistic insights and therapeutic approaches in ACM heart failure
Early detection and prevention of cardiac dysfunction and heart failure induced by cancer chemotherapeutics – Cardio-oncology ERA-CVD 2016 Plus de détails de : Early detection and prevention of cardiac dysfunction and heart failure induced by cancer chemotherapeutics Communication between cardiomyocytes and innate immune cells in failing hearts – CLARIFY ERA-CVD 2016 Plus de détails de : Communication between cardiomyocytes and innate immune cells in failing hearts DETERMINING THE ROLE OF CLINICAL AND EPI-GENETIC RISK MARKERS IN DILATED CARDIOMYOPATHIES AND HEART FAILURE – DETECTIN-HF ERA-CVD 2016 Plus de détails de : DETERMINING THE ROLE OF CLINICAL AND EPI-GENETIC RISK MARKERS IN DILATED CARDIOMYOPATHIES AND HEART FAILURE Heart Failure Rescue by Nutritional Approaches: relevance of mitochondrial substrate utilization – FAT4HEART ERA-CVD 2016 Plus de détails de : Heart Failure Rescue by Nutritional Approaches: relevance of mitochondrial substrate utilization Metabolic Therapy for Managing Diastolic Heart Failure – MINOTAUR ERA-CVD 2016 Plus de détails de : Metabolic Therapy for Managing Diastolic Heart Failure Gene therapy with phosphodiesterases to treat heart failure – PDE4HEART ERA-CVD 2016 Plus de détails de : Gene therapy with phosphodiesterases to treat heart failure Novel RNA based therapies for treatment-resistant forms of severe cardiomyopathy caused by LMNA mutations – VARIATION ERA-CVD 2016 Plus de détails de : Novel RNA based therapies for treatment-resistant forms of severe cardiomyopathy caused by LMNA mutations Targeted LYmphatic and MIcrovessel Treatments in metabolic-DISease HFpEF – LYMIT-DIS ERA-CVD 2016 Plus de détails de : Targeted LYmphatic and MIcrovessel Treatments in metabolic-DISease HFpEF LIPCAR, a prognostic marker of heart failure with reduced ejection fraction – LIPCAR-HF ERA-CVD 2016 Plus de détails de : LIPCAR, a prognostic marker of heart failure with reduced ejection fraction Exploring new pathways in age-related heart diseases – EXPERT ERA-CVD 2016 Plus de détails de : Exploring new pathways in age-related heart diseases Cardiomyocyte - non myocyte interplay as a novel platform for mechanistic insights and therapeutic approaches in ACM heart failure – ACM-HF ERA-CVD 2016 Plus de détails de : Cardiomyocyte - non myocyte interplay as a novel platform for mechanistic insights and therapeutic approaches in ACM heart failure
